Cancer Vaccines Co-Targeting HER2/Neu and IGF1R
Abstract(1) Background: Human epidermal growth factor receptor 2 (HER2)/neu-driven carcinogenesis is delayed by preventive vaccines able to elicit autochthonous antibodies against HER2/neu. Since cooperation between different receptor tyrosine kinases (RTKs) can occur in human as well as in experimental tumors, we investigated the set-up of DNA and cell vaccines to elicit an antibody response co-targeting two RTKs: HER2/neu and the Insulin-like Growth Factor Receptor-1 (IGF1R). (2) Methods: Plasmid vectors carrying the murine optimized IGF1R sequence or the human IGF1R isoform were used as electroporated DNA vaccines. IGF1R plasmids were transfected in allogeneic HER2/neu-positive IL12-producing murine cancer cells to obtain adjuvanted cell vaccines co-expressing HER2/neu and IGF1R. Vaccination was administered in the preneoplastic stage to mice prone to develop HER2/neu-driven, IGF1R-dependent rhabdomyosarcoma. (3) Results: Electroporated DNA vaccines for murine IGF1R did not elicit anti-mIGF1R antibodies, even when combined with Treg-depletion and/or IL12, while DNA vaccines carrying the human IGF1R elicited antibodies recognizing only the human IGF1R isoform. Cell vaccines co-expressing HER2/neu and murine or human IGF1R succeeded in eliciting antibodies recognizing the murine IGF1R isoform. Cell vaccines co-targeting HER2/neu and murine IGF1R induced the highest level of anti-IGF1R antibodies and nearly significantly delayed the onset of spontaneous rhabdomyosarcomas. (4) Conclusions: Multi-engineered adjuvanted cancer cell vaccines can break the tolerance towards a highly tolerized RTK, such as IGF1R. Cell vaccines co-targeting HER2/neu and IGF1R elicited low levels of specific antibodies that slightly delayed onset of HER2/neu-driven, IGF1R-dependent tumors. View Full-Text
- Supplementary File 1:
PDF-Document (PDF, 101 KB)
Share & Cite This Article
De Giovanni, C.; Landuzzi, L.; Palladini, A.; Ianzano, M.L.; Nicoletti, G.; Ruzzi, F.; Amici, A.; Croci, S.; Nanni, P.; Lollini, P.-L. Cancer Vaccines Co-Targeting HER2/Neu and IGF1R. Cancers 2019, 11, 517.
De Giovanni C, Landuzzi L, Palladini A, Ianzano ML, Nicoletti G, Ruzzi F, Amici A, Croci S, Nanni P, Lollini P-L. Cancer Vaccines Co-Targeting HER2/Neu and IGF1R. Cancers. 2019; 11(4):517.Chicago/Turabian Style
De Giovanni, Carla; Landuzzi, Lorena; Palladini, Arianna; Ianzano, Marianna L.; Nicoletti, Giordano; Ruzzi, Francesca; Amici, Augusto; Croci, Stefania; Nanni, Patrizia; Lollini, Pier-Luigi. 2019. "Cancer Vaccines Co-Targeting HER2/Neu and IGF1R." Cancers 11, no. 4: 517.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.